A Single Center Experience Of 480 Intravenous Iron Infusions In An Outpatient Heart Failure Clinic
Asmaa Albuloushi,Leo F. Buckley,Michelle A. Young,Joanne R. Weintraub,Christine Forgeron,David W. Molway,Denise Palmer,Elaine L. Shea,Francis Melanson,Ju Hee Kim,Kristin Kociol,Kristina Velez,Liriany Y. Pimentel,Mohsen Al Zaria,Omar Saleh B Alkhezi,Lina S. Matta,Akshay S. Desai
DOI: https://doi.org/10.1016/j.cardfail.2023.10.262
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Background Intravenous (IV) iron repletion in HF with reduced ejection fraction (HFrEF) improves HF symptoms and reduces total HF hospitalizations. IV iron repletion requires specialized infusion and resuscitation equipment and trained personnel for administration and monitoring. This study sought to describe our center's approach for outpatient administration and monitoring of IV iron to patients with HF. Methods This retrospective cohort study included all patients with HF, regardless of ejection fraction, who received at least one outpatient administration of an IV iron product for clinically indicated treatment of iron deficiency at our center's outpatient HF clinic from June 2015 to December 2021. We assessed changes in ferritin and transferrin saturation, infusion reactions, all-cause hospitalizations and deaths. A severe infusion reaction was defined as any reaction that was life-threatening, lead to emergency department visit, hospitalization or death or resulted in persistent or significant disability. Non-severe infusion reactions included pain or burning at the infusion site, dizziness, headache, nausea or itching that began after IV iron administration. A HF nurse documented any abnormal signs or symptoms that occurred during or up to 30 minutes after the iron infusion. Hospitalizations and deaths were abstracted from the medical record. Results A total of 480 IV iron infusions (ferumoxytol n=368, iron sucrose n=110 and low-molecular weight iron dextran n=2) were administered to 204 patients with HF, including patients that initially started IV iron replacement during hospitalization (n=24) (mean age 66 years, 50% women, 53% HFpEF). The median change from baseline in serum ferritin was 139 ng/dL [n=126; 25th, 75th percentiles: 26, 304] and the median change in transferrin saturation was 11% [n=126;25th, 75th percentiles: 4, 19]. Infusion-related reactions occurred in 15 (7%) patients, including 3 severe reactions requiring glucocorticoid or antihistamine administration and further management or observation in the emergency department. None of these severe reactions required hospitalization. All-cause hospitalization occurred in 103 (51%) patients and 10 (5%) patients died within 6 months of IV iron treatment. Conclusion An outpatient HF clinic can be adapted to efficiently administer IV iron infusions. Adverse events were rare and could be managed with bedside interventions.
cardiac & cardiovascular systems